BioVie Inc. (BIVI)

Market Cap	39.74M
Revenue (ttm)	n/a
Net Income (ttm)	-26.77M
Shares Out	17.74M
EPS (ttm)	-5.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	429,721
Open	2.240
Previous Close	2.230
Day's Range	2.170 - 2.255
52-Week Range	1.040 - 33.100
Beta	1.04
Analysts	Strong Buy
Price Target	30.00 (+1,239.29%)
Earnings Date	Feb 11, 2025

About BIVI

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and chang...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: BIVI
• Website: https://bioviepharma.com

Analyst Forecast

According to one analyst, the rating for BIVI stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target

$30.0

(1,239.29% upside)

Analyst Consensus: Strong Buy